Sexual dysfunction and antipsychotic treatment

Psychoneuroendocrinology

Volumn 28, Issue SUPPL. 1, 2003, Pages 69-82

  Cutler, A J ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Atypical antipsychotics; Hyperprolactinemia; Schizophrenia; Sexual dysfunction

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; DOPAMINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; TRAZADONE; UNCLASSIFIED DRUG; ZIPRASIDONE;

AGRANULOCYTOSIS; AMENORRHEA; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DISTRESS SYNDROME; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION DISORDER; ENDOCRINE DISEASE; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; IMPOTENCE; LIBIDO DISORDER; MENSTRUATION DISORDER; ORGASM DISORDER; PATIENT COMPLIANCE; PRIAPISM; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; REPRODUCTIVE TOXICITY; SCHIZOPHRENIA; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; TREATMENT PLANNING;

EID: 0037216518     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(02)00113-0     Document Type: Article

References (63)

1. Aizenberg D., Zemishlany Z., Dorfman-Etrog P., Weizman A. Sexual dysfunction in male schizophrenic patients. J. Clin. Psychiatry. 56:1995;137-141.
2. American Psychiatric Association, 1997. Practice guideline for the treatment of patients with schizophrenia. Am. J. Psychiatry, 154 (suppl. 4), 1-63.
3. Arvanitis L.A., Miller B.G. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol. Psychiatry. 42:1997;233-246.
4. Barnes T.R.E., Harvey C.A. Psychiatric drugs and sexuality. Riley A.J., Peet M., Wilson C. Sexual Pharmacology. 1993;176-196 Oxford Medical Publications, Oxford.
5. Bobes, J., Rejas, J., Garcia, M., Rico-Villademoros, F., Porras, A., Hernandez, G., 2001. Frequency and management of sexual dysfunction with antipsychotic drugs in schizophrenic patients: results from the EIRE study (poster). Presented at the American Psychiatric Association Annual Meeting, New Orleans, Louisiana, USA.
6. Breier A.F., Malhotra A.K., Su T.P., Pinals D.A., Elman I., Adler C.M., Lafargue R.T., Clifton A., Pickar D. Clozapine and risperidone in chronic schizophrenia: Effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am. J. Psychiatry. 156:1999;294-298.
7. Buckley P.F. Sexuality and Serious Mental Illness. 1999;Harwood Academic Publishers, Amsterdam.
8. Carnahan R.M., Lund B.C., Perry P.J. Ziprasidone, a new atypical antipsychotic drug. Pharmacotherapy. 21:2001;717-730.
9. Collins A.C., Kellner R. Neuroleptics and sexual functioning. Integr. Psychiatry. 4:1986;96-108.
10. Compton M.T., Miller A.H. Priapism associated with conventional and atypical antipsychotic medications: a review. J. Clin. Psychiatry. 62:2001;362-366.
11. Compton M.T., Saldivia A., Berry S.A. Recurrent priapism during treatment with clozapine and olanzapine. Am. J. Psychiatry. 157:2000;659.
12. Crawford A.M., Beasley C.M. Jr., Tollefson G.D. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr. Res. 26:1997;41-54.
13. Dent L.A., Brown W.C., Murney J.D. Citalopram-induced priapism. Pharmacotherapy. 22:2002;538-541.
14. Dickson R.A., Dalby J.T., Williams R., Edwards A.L. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. Am. J. Psychiatry. 152:1995;1102-1103.
15. Emes C.E., Millson R.C. Risperidone-induced priapism. Can. J. Psychiatry. 39:1994;315-316.
16. Finn S.E., Bailey J.M., Schultz R.T., Faber R. Subjective utility ratings of neuroleptics in treating schizophrenia. Psychol. Med. 20:1990;843-848.
17. Frohlich P.F., Meston C.M. Evidence that serotonin affects female sexual functioning via peripheral mechanisms. Physiol. Behav. 71:2000;383-393.
18. Fulton B., Goa K.L. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 53:1997;281-298.
19. Geodon (ziprasidone HCI) Prescribing Information, 2001. Pfizer. Available at: www.pfizer.com/hml/pi's/geodonpi.pdf .
20. Ghadirian A.M., Chouinard G., Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J. Nerv. Ment. Dis. 170:1982;463-467.
21. Gitlin M.J. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J. Clin. Psychiatry. 55:1994;406-413.
22. Goldstein, J.M., Arvanitis, L.A., Cantillon, M., 1997. Low incidence of reproductive/hormonal side effects with 'Seroquel' (quetiapine fumarate) is supported by its lack of elevation of plasma prolactin concentrations. Abstracts of the 36th Annual Meeting of the American College of Neuropsychopharmacology 170 (abstract), Waikoloa, Hawaii, USA.
23. Hamner M.B., Arvanitis L.A., Miller B.G., Link C.G., Hong W.W. Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204, 636). Psychopharmacol. Bull. 32:(636):1996;107-110.
24. Hellewell, J.S.E., 2000. Tolerability and patient satisfaction as determinants of treatment choice in schizophrenia: a multi-national survey of the attitudes and perceptions of psychiatrists towards novel and conventional antipsychotics (poster). Presented at the 13th European College of Neuropsychopharmacology Congress, Munich, Germany.
25. Hovermann P., Nurnbach-Ross B., Albrecht J. Priapism with clozapine therapy. Nervenarzt. 68:1997;75-76.
26. Hummer M., Kemmler G., Kurz M., Kurzthaler I., Oberhauer H., Fleischhacker W.W. Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. Am. J. Psychiatry. 156:1999;631-633.
27. Jibson M.D., Tandon R. New atypical antipsychotic medications. J. Psychiatr. Res. 32:1998;215-228.
28. Kapur S., Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am. J. Psychiatry. 158:2001;360-369.
29. Kasper S., Tauscher J., Kufferle B., Barnas C., Pezawas L., Quiner S. Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacology in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 249:(Suppl. 4):1999;83-89.
30. Keck P. Jr., Buffenstein A., Ferguson J., Feighner J., Jaffe W., Harrigan E.P., Morrissey M.R. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl.). 140:1998;173-184.
31. Kleinberg D.L., Davis J.M., de Coster R., Van Baelen B., Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J. Clin. Psychopharmacol. 19:1999;57-61.
32. Kotin J., Wibert D.E., Verburg D., Soldinger S.M. Thioridazine and sexual dysfunction. Am. J. Psychiatry. 133:1976;82-85.
33. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. 334:(Suppl. 4):1987;1-100.
34. Madhusoodanan S., Brenner R. Risperidone-induced ejaculatory and urinary dysfunction. J. Clin. Psychiatry. 57:1996;549-550.
35. Maizel S., Umansky L., Knobler H.Y. Risperidone-induced priapism. Harefuah. 130:(799):1996;744-745.
36. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry. 151:1994;825-835.
37. Marken P.A., Haykal R.F., Fisher J.N. Management of psychotropic-induced hyperprolactinemia. Clin. Pharm. 11:1992;851-856.
38. Meston C.M., Gorzalka B.B. Psychoactive drugs and human sexual behavior: the role of serotoninergic activity. J. Psychoactive Drugs. 24:1992;1-40.
39. Milner K., Tandon R., Tomori O., Florence T. Psychotropic medications and sexual dysfunction. Buckley P.F. Sexuality and Serious Mental Illness. 1999;Harwood Academic Publishers, Amsterdam.
40. Mitchell J.E., Popkin M.K. Antipsychotic drug therapy and sexual dysfunction in men. Am. J. Psychiatry. 139:1982;633-637.
41. Moinfar N., Goad S., Brink D.D., Klinger R.L. Clozapine-related priapism. Hosp. Community Psychiatry. 45:1994;1044.
42. Mullen J., Reinstein M., Bari M., Ginsberg L., Sandler N. Quetiapine and risperidone in outpatients with psychotic disorders: results of the QUEST trial. Eur. Neuropsychopharmacol. 9:(Suppl. 5):1999;S267.
43. Myrick H., Markowitz J.S., Henderson S. Priapism following trazodone overdose with cocaine use. Ann. Clin. Psychiatry. 10:1998;81-83.
44. Nicolson R., McCurley R. Risperidone-associated priapism. J. Clin. Psychopharmacol. 17:1997;133-134.
45. Pais V.M., Ayvazian P.J. Priapism from quetiapine overdose: first report and proposal of mechanism. Urology. 58:2001;462.
46. Petty R.G. Prolactin and antipsychotic medications: mechanism of action. Schizophr. Res. 35:(1001):1999;S67-S73.
47. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br. J. Psychiatry. 166:1995;712-726.
48. Peuskens J. Prolactin elevation and sexual dysfunction. Peuskens J. A Literature Review of "Prolactin in Schizophrenia." Clear Perspectives: Management Issues in Schizophrenia. 1:(3):1997;17-27.
49. Peuskens J., Link C.G. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr. Scand. 96:1997;265-273.
50. Peuskens J., Sienaert P., De Hert M. Sexual dysfunction: the unspoken side effect of antipsychotics. Eur. Psychiatry. 13:(Suppl. 1):1998;23S-30S.
51. Raja M. Risperidone-induced absence of ejaculation. Int. Clin. Psychopharmacol. 14:1999;317-319.
52. Rand E.H. Priapism in a patient taking sertraline. J. Clin. Psychiatry. 59:1998;538.
53. Rao M.L., Gross G., Strebel B., Halaris A., Huber G., Braunig P., Marler M. Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol. Psychiatry. 35:1994;151-163.
54. Rosen S.I., Hanno P.M. Clozapine-induced priapism. J. Urol. 148:1992;876-877.
55. Seroquel (quetiapine fumarate) Tablets Prescribing Information, 2001. AstraZeneca.
56. Stimmel G.L., Gutierrez M.A., Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin. Ther. 24:2002;21-37.
57. Tekell J.L., Smith E.A., Silva J.A. Prolonged erection associated with risperidone treatment. Am. J. Psychiatry. 152:1995;1097.
58. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley C. Jr., Tollefson G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 17:1997;407-418.
59. Wesby R., Bullimore E., Earle J., Heavey A. A survey of psychosexual arousability in male patients on depot neuroleptic medication. Eur. Psychiatry. 11:1996;81-86.
60. Wilson C.A. Pharmacological targets for the control of male and female sexual behaviour. Riley A.J., Peet M., Wilson C. Sexual Pharmacology. 1993;1-58 Oxford Medical Publications, Oxford.
61. Worrel J.A., Marken P.A., Beckman S.E., Ruehter V.L. Atypical antipsychotic agents: a critical review. Am. J. Health Syst. Pharm. 57:2000;238-255.
62. Ziegler J., Behar D. Clozapine-induced priapism. Am. J. Psychiatry. 149:1992;272-273.
63. Zyprexa (Olanzapine) Prescribing Information, 2000. Eli Lilly and Company.